Approval for Phase IV clinical trial officially on U.S. National Institutes of Health (NIH) website
KUALA LUMPUR, 27 NOVEMBER 2020 - Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code: 9601) is pleased to inform that the approval from US Food and Drug Administration (“FDA”) to E-MO Biology Inc. (ËBI”) for the commencement of its Phase IV clinical trial, had been officially published on the National Institutes Of Health (NIH) website: https://www.clinicaltrials.gov/ct2/show/NCT04639375
The objective of the Phase IV clinical trial is to understand how well the vaccine works when it is introduced to the public and to collect additional information about the side effects or its long-term risks as well as its potential benefits.
HWGB Biotech’s General Manager (Medical & Pharmaceutical Research), Dr. Yaman Walid Kassab said, "This clinical trial published in US Department of Health and Human Services reflects a significant progress in our vaccination development in collaboration with EBI. We look forward to learning more about the potential of the poliomyelitis virus vaccine (PVV) in this clinical trial on patients living with COVID-19 and to continue the momentum toward our goal of providing a safer and affordable COVID-19 vaccine to the public."
Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare related industry which mainly involved in health supplement, biotechnology and health technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of investment holdings; manufacturing of wires and cables and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; trading of wires and cables; and travel agent and tour related services.
HWGB Biotech Sdn Bhd, was incorporated on 18 June 2012 under the Companies Act, 1965 under the former name of HWG Consortium Sdn Bhd and changed to its current name on 22 May 2020. HWGB Biotech is principally involved in the distribution of all kinds of biotechnology products, bioinformatics diagnostic tools, all medical engineering equipment along with software developments and tools as well as to patent all original products and by-products, technologies and software developed or sourced by the company.
Dr.Yaman Walid Kassab is an assistant Professor of Clinical Pharmacy. He obtained his PhD in Clinical Pharmacy at University Science Malaysia (USM) in 2013. He possesses 7 years of experience in the academia, specifically in the pharmacotherapy field. He is actively involved in medical research and publication and has published more than 40SCOPUS/ISI indexed research papers and has supervised more than 50 research projects and 20 postgraduate research students. He is also serving as an editorial Board member of several reputed international journals like “Frontiers in Pharmacology”, “Archives of Pharmacy Practice (APP)” , “Journal of Medical and Pharmaceutical Innovation (JMPI)” , ”Annals of Cardiology and Cardiovascular Diseases” , “Updates in Public Health and Preventive Medicine” He has been a member of many international professional bodies such as International Association of Therapeutic Drug Monitoring & Clinical Toxicology in CANADA, Syndicate of Syrian Pharmacists, Malaysian Association of Education in Medicine & Health Sciences, Malaysian Pharmaceutical Society.
E-Mo Biology Inc. (“EBI”) was incorporated in the state of California in the United States of America on 24 May 2020. It is principally involved in conducting biology research and development activities and is the sponsor of a study which indicates booster polio vaccine to reduce Covid-19 SARS-COV-2 infection and severity.
EBI is founded by Dr. Xie QiYi, who serves as its Managing Director of EBI. He has over 30 years of experience in areas of public health and infection disease control. He was also involved in the development of medical and diagnostic devices, with focus on Quality, Regulatory and Clinical Affairs for quality systems.